hcp-enrolling-02-module1.3

PROLASTIN DIRECT: One source for every alpha-1 need

Just one number connects your patients to comprehensive, personalized alpha-1 support: 1-833-PHONEA1 (746-6321).

hcp-enrolling-03-module4.0

Enrollment is easy

Blue form icon

Complete enrollment form

  • Download, complete, and fax the PROLASTIN DIRECT enrollment form to 888-817-2098
  • Prescribe PROLASTIN-C LIQUID for your patients with a positive diagnosis of severe alpha-1 with clinical evidence of emphysema
  • Choose Accredo as the dispensing pharmacy. Accredo is the exclusive dispensing pharmacy for PROLASTIN-C LIQUID
Orange umbrella icon

PROLASTIN DIRECT takes care of the rest so you and your practice can have more time managing your patients with alpha-1

hcp-enrolling-05-text

Enroll your patients in the PROLASTIN DIRECT program

DOWNLOAD ENROLLMENT FORM

HCP Enrol Question? Call

Questions? Call PROLASTIN DIRECT at 1-833-PHONEA1 (746-6321)

hcp_isi

IMPORTANT SAFETY INFORMATION

PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use
  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established
 

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

hcp-enrolling-06-references

References:

1. Data on file, PROLASTIN DIRECT program. 2. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.